Fig. 8
From: Anti-VEGF therapy prevents Müller intracellular edema by decreasing VEGF-A in diabetic retinopathy
Changes in mRNA and protein levels of Dp71 and GS in glyoxal-treated rMC-1 cells treated with or without ranibizumab. The (a) mRNA and (b) protein level of Dp71 in glyoxal-treated rMC-1 cells with or without ranibizumab. The (c) mRNA and (d) protein level of GS in glyoxal-treated rMC-1 cells with or without ranibizumab. Data are expressed as mean ± SE (n = 8 in [a, c], n = 4 in [b, d], *P < 0.05). N: normal control; G: rMC-1 cells treated with 1 mM glyoxal; G + R: rMC-1 cells treated with glyoxal and ranibizumab